Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Alizé Reveals Data on ALL Therapy Asparec

By Drug Discovery Trends Editor | December 3, 2009

Alizé Pharma, a group of companies developing innovative therapeutics for metabolic diseases and cancer, has developed an improved L-asparaginase product with increased potency, reduced immunogenicity and longer duration of action. The product, Asparec, involves the use of a state-of-the-art PEGylation technology. Key preclinical data supporting the development of this product as second line therapy in ALL will be presented at the 51st ASH Annual Meeting to be held in New Orleans, LA on December 5-8, 2009.

Alizé’s Asparec program focuses on a PEGylated r-crisantaspase product that has the potential to significantly impact the L-asparaginase market by becoming the reference product for second line therapy. L-asparaginases are widely used in the treatment of ALL. But although Escherichia coli -derived L-asparaginase products are used as first line therapy, there is a high incidence of allergic and immunogenicity reactions, requiring the use of second line products, such as Erwinia chrysanthemi-derived L-asparaginase (crisantaspase).

Key results to be presented at ASH indicate that the Asparec product is ideally suited as second line therapy, as it is structurally similar to crisantaspase, but is both longer acting and less immunogenic thanks to its PEGylated nature. Results of pharmacokinetic and pharmacodynamic studies in mice revealed that the Asparec product was at least 50 times more potent and was longer-acting than crisantaspase (Erwinase) in depleting blood asparagine levels. In addition, PEGylation markedly reduced the immunogenicity vs Erwinase as assessed by the antibody titers measured during eight weeks of chronic treatment in mice.

“The preclinical results for our Asparec program are indicative of a therapeutic potential, fulfilling important medical needs for ALL patients,” says Alizé Pharma president and founder, Thierry Abribat. “They also show Alizé Pharma has a real business opportunity to take a leading position in the L-asparaginase market space. We will be actively seeking a commercial partner early in the development process according to our business strategy and to ensure timely take-up of the opportunity.”

Date: November 17, 2009
Source: Alizé Pharma 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50